Sexual Health & Dysfunction: A Complete Clinical Guide

Written by Empire Medical Training Editorial Team

Medically reviewed by Betsy Greenleaf, DO Board-Certified OB/GYN & Urogynecologist; Empire Director of Anti-Aging

Updated June 2026 ·18 min read

Sexual dysfunction is one of the most common — and most under-addressed — concerns clinicians encounter. It affects men and women across every age group, it frequently signals deeper medical problems, and yet it is routinely left unspoken in the exam room. This pillar guide is designed to be an honest, clinical reference: what sexual dysfunction actually is, how often it occurs, what causes it, how it is evaluated, and the real range of treatments available today. From there, the individual guides linked throughout go deeper on each condition and therapy.

Because sexual health is a Your-Money-or-Your-Life medical topic, accuracy and honesty matter. Throughout, we distinguish clearly between what is FDA-approved, what is used off-label, and what remains investigational — and we hedge efficacy claims accordingly. Nothing here is medical advice or a treatment protocol; it is clinical education for providers and an orientation for patients deciding whether to raise the subject with their physician.

What is sexual dysfunction?

Sexual dysfunction is a broad term encompassing the various issues that prevent individuals from experiencing satisfaction during sexual activity. These difficulties can affect any phase of the sexual response cycle — desire, arousal, orgasm, and resolution. The World Health Organization defines it as a person's inability to participate in a sexual relationship as he or she would wish, while the DSM-5 adds an important threshold: a diagnosis generally requires that the difficulty be persistent and cause genuine distress or interpersonal strain. An occasional off night is not a disorder; a recurrent, distressing pattern is.

The model Empire's curriculum teaches is fundamentally biopsychosocial. Sexual function is not a simple plumbing problem; it sits at the intersection of biology, psychology, and relationship. The brain is the central sexual organ, and the autonomic nervous system is the switchboard. As Dr. Greenleaf puts it, the parasympathetic system is “rest, digest, sex, and healing,” while the sympathetic system is “fight, flight, or fright” — and the two cannot coexist. When the body is in a stress state, blood flow and energy are shunted away from reproduction toward survival. “Without brain stimulation, all the Viagra in the world will not function.”

This is why the field has moved beyond the old linear Masters and Johnson response curve (desire → excitement → plateau → orgasm → resolution). The Basson model, especially for women and long-term couples, recognizes that arousal can precede desire: a person who is receptive to intimacy and “goes through the motions” can build psychological arousal and pelvic blood flow, with desire following. Explaining this model to patients often reduces the anxiety that surrounds sex as relationships mature. The practical takeaway, repeated throughout the training, is to look at the roots under the tree — sexual dysfunction is a symptom, and the clinician's job is to find what it is pointing to.

How common is sexual dysfunction?

Sexual dysfunction is far more common than the silence around it suggests. Studies estimate that roughly 43% of women and 31% of men experience some form of sexual dysfunction, and prevalence climbs with age and with conditions such as diabetes, cardiovascular disease, metabolic syndrome, and mood disorders. In specific populations the numbers are striking: low libido affects an estimated 27–52% of menopausal women, and erectile dysfunction affects over half of men between 40 and 70.

Critically, these figures are considered grossly underreported. The reasons are not mysterious — embarrassment, stigma, and the taboo nature of the subject keep patients from raising it, and many clinicians never ask. The result is a large, treatable problem hiding in plain sight. That gap is also why the first clinical skill in this field is not a procedure but a posture: building rapport and creating a comfortable, non-judgmental, confidential environment so the conversation can happen at all. When providers signal that sexual health is a legitimate part of the visit, patients disclose concerns they have carried in silence for years.

Male sexual dysfunction

In men, the two most common presentations are erectile dysfunction and premature ejaculation, though low desire and ejaculatory and orgasmic disorders also occur.

Erectile dysfunction

Erectile dysfunction (ED) is the most common sexual dysfunction in men, affecting more than 50% of men aged 40 to 70. It is defined by difficulty achieving or maintaining an erection sufficient for satisfying activity, and it can stem from vascular, neurological, hormonal, or psychological factors — usually a combination. The mechanism is fundamentally about blood flow: sexual stimulation triggers the release of nitric oxide, which relaxes penile smooth muscle and allows the corpora cavernosa to engorge while the tunica albuginea traps the blood. Anything that impairs that vascular cascade can impair erection.

This is also why ED is, in Dr. Greenleaf's phrase, the “canary in the coal mine” for cardiovascular disease. ED frequently precedes overt heart disease by several years; one study found that men in their 40s with erection problems but no other cardiac risk factors had an 80% future risk of heart disease, and men who developed ED were nearly twice as likely to experience a subsequent cardiovascular event. The clinical lesson is to treat new-onset ED as a prompt for cardiovascular evaluation, not just a prescription request.

Premature ejaculation

Premature ejaculation (PE) is defined by the International Society for Sexual Medicine as ejaculation that consistently occurs within about one minute of penetration (lifelong PE) or a clinically significant reduction in latency to around three minutes or less (acquired PE), together with the inability to delay ejaculation and resulting personal distress. Reported prevalence ranges widely because definitions vary. Management spans behavioral techniques, pelvic-floor work, topical desensitizing agents, and pharmacologic options; the specifics are covered in the dedicated guide and taught in depth in Empire's course.

Female sexual dysfunction

Female sexual dysfunction spans four overlapping domains — desire, arousal, orgasm, and pain — and is at least as common as male dysfunction, affecting an estimated 43% of women. The validated Female Sexual Function Index assesses exactly these domains, and effective care usually means addressing more than one at once.

Desire. Low libido in women — hypoactive sexual desire disorder — is especially common around menopause. As Dr. Greenleaf emphasizes, “there is no horny pill,” because the brain is the most important sexual organ; stress reduction and the psychological drivers of desire cannot be packaged into a tablet. Hormones are “a tool, not the answer,” and even hormone therapy will underperform if stress is not addressed.

Arousal and orgasm. Female arousal and orgasm disorders involve difficulty attaining the genital engorgement, lubrication, and rhythmic pelvic response that the Basson model describes. Because arousal can precede desire, physiologically stimulating approaches — addressing blood flow, sensation, and the mind-body connection — can sometimes start the cycle that desire then follows.

Pain and genitourinary changes. Vaginal dryness and genitourinary syndrome of menopause (GSM) result from falling estrogen, producing thinning, dryness, irritation, and painful intercourse. Prevalence of vaginal dryness in postmenopausal women ranges widely across studies but is very high. This domain is highly treatable, and the dedicated guide covers the options in detail.

The causes of sexual dysfunction

Sexual dysfunction is almost always multifactorial. Dr. Greenleaf's framing — look at the roots under the tree — means systematically considering several overlapping categories rather than settling on the first plausible explanation.

• Vascular. Erections and genital arousal both depend on nitric-oxide-mediated vasodilation and healthy blood flow. Atherosclerosis, hypertension, diabetes, and metabolic disease impair that flow — which is why ED and cardiovascular disease are so tightly linked.
• Hormonal. Low testosterone in men and estrogen decline in women both affect desire, tissue health, and response. Yet the relationship is imperfect: many men with low testosterone are asymptomatic, while many with low libido have normal levels — a reminder that hormones are one input, not the whole story.
• Neurological. The autonomic nervous system, spinal reflex arcs, and conditions such as diabetes, herniated discs, and pelvic nerve injury can disrupt the signaling that drives arousal and orgasm.
• Psychological and relational. Stress, anxiety, depression, trauma, and relationship dynamics are central. “Stress is the biggest killer of reproduction, fertility, and libido,” and modern stressors — work, illness, poor diet, toxins, gut-microbiome shifts — keep the body locked in a sympathetic state where intimacy cannot thrive.
• Medications and substances. Antidepressants, antihypertensives, hormonal contraceptives, alcohol, and other agents commonly contribute and are often the most easily reversible cause.

How sexual dysfunction is evaluated

A sound workup rests on three pillars: a careful history, a focused examination, and targeted laboratory and specialized testing — all built on a foundation of rapport and confidentiality.

The history establishes the specific nature, onset, duration, and frequency of the problem, the factors that worsen or relieve it, and the past and current relationship context, alongside a full medical, psychosocial, and medication review. Validated questionnaires structure this: the International Index of Erectile Function for men and the Female Sexual Function Index for women are widely used, validated instruments. Throughout, the principle is to take a whole-body, mind-body-spirit view and look for sources outside the pelvis — diabetes, cardiovascular disease, neurological conditions, and psychological stressors.

The physical exam includes a general assessment plus a focused genital exam, vascular checks, and where indicated neurologic testing such as the bulbocavernosus reflex to confirm an intact sacral reflex arc. Laboratory testing is guided by the clinical picture and may include testosterone and other hormones, blood glucose, lipids, thyroid, and inflammatory markers. More specialized studies — nocturnal tumescence testing, penile or clitoral Doppler ultrasound, and nerve studies — are reserved for unclear or treatment-refractory cases. The specifics of when and how to deploy each are taught in Empire's course.

The treatment landscape

Treatment has expanded dramatically, and matching the option to the patient — and being honest about the evidence behind each — is the core clinical skill. The major categories below each have a dedicated guide.

Oral medications (PDE5 inhibitors)

PDE5 inhibitors — sildenafil, tadalafil, vardenafil, and avanafil — are the FDA-approved first-line therapy for ED. They block phosphodiesterase type 5, preventing the breakdown of cyclic GMP so that nitric-oxide-driven vasodilation is sustained. Importantly, they do not create arousal; they amplify a response the body already initiates, which is why brain stimulation and relaxation remain prerequisites.

Injections and devices

For men who do not respond to oral agents, ED injections and devices — intracavernosal agents such as alprostadil and compounded combinations, vacuum erection devices, constriction rings, and penile implants — offer effective alternatives, with high satisfaction rates for implants in appropriately selected patients. Dosing, combinations, and technique are taught in the course rather than reproduced here.

Shockwave therapy

Low-intensity shockwave therapy uses acoustic waves to stimulate angiogenesis, tissue remodeling, and nitric oxide production in penile tissue. It is genuinely promising but still emerging: protocols are not standardized, and the Sexual Medicine Society of North America recommends it be used under research protocols pending more robust data.

PRP and regenerative approaches

Platelet-rich plasma (PRP) uses the patient's own concentrated growth factors, injected into genital tissue to stimulate healing and blood flow. Mechanistically plausible and marketed widely (including under branded names), its clinical evidence is mixed — some trials show benefit, at least one randomized study showed none.

Hormones

Hormones and sexual function are deeply intertwined: testosterone in men, and estrogen, DHEA, and testosterone in women, including low-dose local vaginal formulations for GSM. For a fuller treatment, see Empire's hormone replacement therapy guide and its spokes on testosterone replacement and BHRT for women.

Peptides

Among peptides, PT-141 (bremelanotide) is a melanocortin receptor agonist that works centrally to increase desire and arousal in both sexes. The injectable form is FDA-approved for premenopausal women with HSDD; use in men is off-label and compounded. It illustrates the field's central honesty principle: know exactly what is approved, what is off-label, and what is investigational before you prescribe.

Sexual health guides

Below is a directory of the in-depth guides in this cluster, grouped by topic. Each one goes deeper on evaluation, evidence, and the clinical reasoning behind treatment — with the protocols themselves taught in Empire's course.

The regenerative frontier: shockwave & PRP, honestly

Two regenerative approaches dominate the sexual-wellness conversation, and both deserve clear-eyed framing rather than hype. Low-intensity shockwave therapy delivers acoustic pulses to penile tissue to trigger angiogenesis, tissue remodeling, and nitric oxide release. The mechanism is sound and side effects in trials have been minor, but protocols vary enormously — shock counts, energy settings, and session numbers differ across studies — and the comparative efficacy of radial versus focused waves remains unsettled. A randomized, sham-controlled trial at the Cleveland Clinic is underway precisely because the evidence base is not yet definitive. The honest position, echoing the Sexual Medicine Society of North America, is that shockwave shows real promise but should currently be offered under careful, well-documented protocols.

PRP sits in a similar place. Concentrated autologous growth factors are injected into genital tissue to stimulate microvascular healing, with real results typically emerging over four to six weeks as those growth factors do their work. Animal data and some clinical studies suggest benefit; however, at least one randomized, placebo-controlled trial found no significant difference from placebo, and sample sizes and protocols remain heterogeneous. PRP is reassuringly safe — it uses the patient's own blood — but providers should present it as emerging, not established, and avoid implying certainty the data do not support. Offering either therapy responsibly means honest informed consent about exactly where the evidence stands.

Safety and the sensitive conversation

Two kinds of safety matter in this field. The first is clinical: proper patient selection, sterile technique for any injection, awareness of contraindications, and knowing which findings warrant referral. Urgent conditions exist — priapism, for example, is an emergency requiring immediate evaluation — and several presentations call for a multidisciplinary approach spanning urology, gynecology, pelvic-floor physical therapy, mental health, and cardiology. Sexual pain in particular is a complex, multifactorial domain that the curriculum treats as its own discipline.

The second is the safety of the conversation itself. Because stigma keeps patients silent, the clinician's most important tool is a welcoming, non-judgmental, confidential environment that makes it acceptable to raise concerns. That posture is not soft skill garnish — it is what allows accurate diagnosis to happen at all. Treating sexual health as the legitimate medical field it is, with the same matter-of-fact professionalism applied to any other system, is the foundation everything else rests on.

What sexual health treatment costs

For patients, cost varies widely by condition and treatment. Oral PDE5 inhibitors are relatively inexpensive, while device-based, regenerative, and procedure-based options (shockwave, PRP, implants, vaginal rejuvenation) cost considerably more and are typically not covered by insurance, since many are considered elective or lack reimbursement codes. Rather than quote precise figures that drift with market and formulation, the honest answer is that pricing is condition- and practice-specific and should be confirmed with the prescribing clinician. Our dedicated cost of ED treatment guide walks through realistic ranges.

For providers, the more useful question is the business model. As the curriculum covers, sexual wellness is well suited to a cash-pay or membership structure: it allows longer, more thorough appointments, frees care from insurance constraints, and creates a reliable recurring revenue stream — but that margin is only legitimate when the underlying care is properly trained, sourced, and documented.

How providers get trained

Licensed physicians, nurse practitioners, physician assistants, and nurses can all add sexual health to their scope with appropriate training. A strong program goes well beyond a symptom list — it teaches the biopsychosocial reasoning behind sexual function, evaluation across both sexes, evidence-honest treatment selection, hands-on regenerative and injection technique, and how to build a sexual wellness service line responsibly. Empire's sexual dysfunction curriculum, developed by Dr. Betsy Greenleaf, is structured exactly this way and sits within the broader Academy of Anti-Aging & Functional Medicine, alongside hormone replacement, peptide therapy, and regenerative medicine. To go deeper on a specific condition or therapy, explore the guides in the directory above or return to the Resource Center.